Galapagos is a leading biotechnology brand dedicated to revolutionizing patient outcomes through groundbreaking science and innovation. With a focus on discovering, developing, and commercializing innovative medicines, Galapagos is committed to improving the lives of patients worldwide by addressing high unmet medical needs. Their comprehensive research and development capabilities encompass various drug modalities, including small molecules and cell therapies.

Galapagos boasts a robust portfolio covering a wide range of therapeutic areas such as immunology, oncology, and other indications. Notably, their approved medicines for rheumatoid arthritis and ulcerative colitis are available in Europe and Japan. In 2022, Galapagos expanded its expertise into oncology, CAR-T, and antibody-therapy research and development through strategic acquisitions of CellPoint and AboundBio.

These acquisitions enable Galapagos to pioneer a decentralized point-of-care manufacturing model and develop next-generation CAR-Ts and biologicals, potentially transforming the field. With a global presence spanning multiple countries, Galapagos employs over 1,200 dedicated professionals. Their passionate team, united by a shared vision, embodies an entrepreneurial spirit and a collaborative mindset.

Discover the new Galapagos, characterized by a new purpose and a fresh look, as they continue to push boundaries and deliver life-changing solutions for patients worldwide